Karel A. Hinnen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Karel A. Hinnen has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Marco van Vulpen
4 shared publicationsJan J. Battermann
Department of Radiation Oncology, University Medical Center Utrecht, Utrecht
3 shared publications- Joep G. H. van Roermund
Department of Urology, Maastricht University Medical Center+, Maastricht, The Netherlands
3 shared publications Ina M. Jürgenliemk-Schulz
Department of Radiation Oncology
2 shared publicationsMarinus A. Moerland
Department of Radiation Oncology
2 shared publicationsEllen M. A. Roeloffzen
Department of Radiation Oncology, University Medical Center Utrecht, Utrecht
1 shared publication
Latest Publications
- 10 January 2011
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 11 (1) , 115-123
Predictors in the outcome of125I brachytherapy as monotherapy for prostate cancer
A number of different prostate cancer treatment modalities exist. Nomograms are used to assist clinicians and patients in choosing the most appropriate treatment. However, the predicted outcome for (125)I brachytherapy is much worse than what would be expected considering the actual survival rates. This underestimation may result in suboptimal treatment decisions. Therefore, better predictors for outcome after (125)I brachytherapy are necessary. The following factors, which may either influence outcome or predict outcome after brachytherapy, are discussed: tumor characteristics and risk stratification, patient age at treatment, obesity, adjuvant androgen-deprivation therapy, prostate-specific antigen bounce, implantation technique and dosimetry. For the prediction of outcome after (125)I brachytherapy, as long as the quality of the implant is optimal, only high-risk prostate cancer was found to have a negative impact on outcome.
- 10 January 2011
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 11 (1) , 115-123
Predictors in the outcome of125I brachytherapy as monotherapy for prostate cancer
A number of different prostate cancer treatment modalities exist. Nomograms are used to assist clinicians and patients in choosing the most appropriate treatment. However, the predicted outcome for (125)I brachytherapy is much worse than what would be expected considering the actual survival rates. This underestimation may result in suboptimal treatment decisions. Therefore, better predictors for outcome after (125)I brachytherapy are necessary. The following factors, which may either influence outcome or predict outcome after brachytherapy, are discussed: tumor characteristics and risk stratification, patient age at treatment, obesity, adjuvant androgen-deprivation therapy, prostate-specific antigen bounce, implantation technique and dosimetry. For the prediction of outcome after (125)I brachytherapy, as long as the quality of the implant is optimal, only high-risk prostate cancer was found to have a negative impact on outcome.
- 9 November 2010
- Published by Wiley in BJU International
- Vol. 107 (12) , 1906-1911
Survival after prostate brachytherapy in patients aged 60 years and younger
Study Type – Aetiology (prospective cohort) Level of Evidence 2B OBJECTIVE: • To compare survival after prostate brachytherapy in patients aged ≤60 years with patients aged >60 years. patientS AND METHODS: • We analysed 419 locally confined prostate cancer patients, treated between 1989 and 2001 with I‐125 implantation monotherapy. • Endpoints were biochemical failure (BF) according to the +2 ng/mL definition, disease‐specific and overall survival. • Patients were subdivided into age ≤60 years and age >60 years. • Cox proportional‐hazards regression analyses were performed to study the independent effect of age on BF and disease‐specific survival. RESULTS: • The younger cohort consisted of 87 patients (21%), with smaller prostate volumes and a lower average prostate cancer risk class than the older cohort, consisting of 332 patients (79%). Mean follow‐up was 9.1 years (± sd 2.8) for the younger cohort and 8.3 years (± sd 2.9) for the older cohort. • The 10‐year (95% CI) freedom from BF, disease‐specific survival and overall survival rates were 63% (51–75), 87% (78–96) and 81% (69–89), respectively, for the younger cohort and 46% (39–54), 83% (78–89) and 60% (54–66), respectively, for the older patient cohort. • Although a trend for better freedom from BF and disease‐specific survival was observed in younger patients, the difference proved not clinically significant. CONCLUSION: • Prostate cancer risk group and the year of treatment relate to outcome, but not age. With respect to prostate cancer curability, there seems no objection to offer brachytherapy to patients aged 60 years and younger.
- 9 November 2010
- Published by Wiley in BJU International
- Vol. 107 (12) , 1906-1911
Survival after prostate brachytherapy in patients aged 60 years and younger
Study Type – Aetiology (prospective cohort) Level of Evidence 2B OBJECTIVE: • To compare survival after prostate brachytherapy in patients aged ≤60 years with patients aged >60 years. patientS AND METHODS: • We analysed 419 locally confined prostate cancer patients, treated between 1989 and 2001 with I‐125 implantation monotherapy. • Endpoints were biochemical failure (BF) according to the +2 ng/mL definition, disease‐specific and overall survival. • Patients were subdivided into age ≤60 years and age >60 years. • Cox proportional‐hazards regression analyses were performed to study the independent effect of age on BF and disease‐specific survival. RESULTS: • The younger cohort consisted of 87 patients (21%), with smaller prostate volumes and a lower average prostate cancer risk class than the older cohort, consisting of 332 patients (79%). Mean follow‐up was 9.1 years (± sd 2.8) for the younger cohort and 8.3 years (± sd 2.9) for the older cohort. • The 10‐year (95% CI) freedom from BF, disease‐specific survival and overall survival rates were 63% (51–75), 87% (78–96) and 81% (69–89), respectively, for the younger cohort and 46% (39–54), 83% (78–89) and 60% (54–66), respectively, for the older patient cohort. • Although a trend for better freedom from BF and disease‐specific survival was observed in younger patients, the difference proved not clinically significant. CONCLUSION: • Prostate cancer risk group and the year of treatment relate to outcome, but not age. With respect to prostate cancer curability, there seems no objection to offer brachytherapy to patients aged 60 years and younger.
- 31 July 2010
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 96 (1) , 30-33
Loose seeds versus stranded seeds in I-125 prostate brachytherapy: Differences in clinical outcome
- 31 July 2010
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 96 (1) , 30-33
Loose seeds versus stranded seeds in I-125 prostate brachytherapy: Differences in clinical outcome
- 1 April 2010
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 76 (5) , 1433-1438
Long-Term Biochemical and Survival Outcome of 921 Patients Treated With I-125 Permanent Prostate Brachytherapy
- 1 April 2010
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 76 (5) , 1433-1438
Long-Term Biochemical and Survival Outcome of 921 Patients Treated With I-125 Permanent Prostate Brachytherapy